Information on shares held by the Shionogi Group and the purpose of the shareholdings are described in “Part I Corporate Information, IV Status of Company, 4. Corporate Governance, (5) Shareholdings” of the Securities Report for the 159th Period (from April 1, 2023 to March 31, 2024).


For your information: pages 73 to 78 of the Securities Report for the 159th Period(Fiscal Year Ended March 2024).

 

Of the unlisted shares not described above, the shares of ViiV Healthcare Ltd. (hereafter, “ViiV”), which Shionogi holds through its European subsidiary Shionogi B.V., were acquired following a revision of the agreement with ViiV in October 2012. In the framework that was agreed upon with ViiV, the Shionogi Group transferred its rights to the anti-HIV drugs that was being developed by the ViiV-Shionogi joint venture to ViiV in return for a 10 percent equity stake in ViiV. The Shionogi Group also retained rights to royalties at a fixed percentage of sales of the anti-HIV drugs. The Shionogi Group holds ViiV shares for the business purpose of participating in ViiV management as a shareholder, and contributing to the treatment of HIV patients and the prevention of the disease, as well as for the purpose of ensuring medium- to long-term revenues through dividend income from its shareholdings.